ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FDBK Feedback Plc

97.50
-2.50 (-2.50%)
Last Updated: 11:34:19
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -2.50% 97.50 95.00 100.00 100.00 97.50 100.00 7,300 11:34:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.2188 -4.46 13M

Feedback PLC Disposal (0664X)

03/05/2016 12:00pm

UK Regulatory


Feedback (LSE:FDBK)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Feedback Charts.

TIDMFDBK

RNS Number : 0664X

Feedback PLC

03 May 2016

3 May 2016

Feedback plc

("Feedback" or the "Company")

Disposal

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce that it has agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of GBP46,000 (the "Disposal").

Feedback invested GBP1,000 in Stone Checker in July 2015 and subsequently licensed its TexRAD software to Stone Checker for exclusive use in urolithiasis (kidney stones). On 28 September 2015, Feedback announced the intention to develop a product incorporating TexRAD for kidney stones. It was further stated that the vision of Stone Checker was to develop a composite risk stratification software product incorporating TexRAD CT texture analysis with other known clinical markers. This integrated product could potentially assist urologists and radiologists to provide better patient management and treatment decisions for improved patient outcomes.

Stone Checker is making good progress and is reaching the stage where it will require substantial additional investment. Feedback has already announced that it is committing significant resources in developing a lung cancer stratification tool in conjunction with Alliance Medical Group. Accordingly, although urolithiasis could be an exciting application for TexRAD, the directors of Feedback are of the opinion that they should focus investment in TexRAD's use in oncology. The sale of the equity interest in Stone Checker will generate a profit of GBP45,000 before expenses. Feedback will continue to receive royalty and licence payments should Stone Checker achieve commercial success. The sale proceeds will be used by Feedback for general corporate purposes.

Stone Checker is currently a pre-revenue company which made a loss before tax for the period ending 29 February 2016 of GBP154.

Related Party Transaction

Trevor Brown is a director and substantial shareholder in Feedback. Dr Balaji Ganeshan is a director of Stone Checker representing Feedback and is expected to remain a director of both Feedback and Stone Checker after the Disposal. Accordingly, the Disposal constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies ("AIM Rules"). The other three directors of Feedback have no direct involvement in Stone Checker and are not related to the purchaser of Feedback's holding and are therefore deemed to be independent under the AIM Rules for the purposes of considering the related party transaction (the "Independent Directors"). The Independent Directors, having consulted with Allenby Capital Limited, the Company's nominated adviser, consider that the terms of the disposal are fair and reasonable insofar as the Company's shareholders are concerned.

For further information, contact:

Feedback plc

Tom Charlton / Mike Hayball

Tel: 01954 718072

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Simon Clements / James Thomas

Tel: 020 3328 5656

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey

Tel: 020 7469 0936

This information is provided by RNS

The company news service from the London Stock Exchange

END

DISAJMMTMBAMBFF

(END) Dow Jones Newswires

May 03, 2016 07:00 ET (11:00 GMT)

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Your Recent History

Delayed Upgrade Clock